Treace Medical Concepts (TMCI) Price to Sales (2021 - 2026)

Treace Medical Concepts (TMCI) has reported Price to Sales for 6 consecutive years, with 5.7 the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, Price to Sales fell 27.23% year-over-year to 5.7; the trailing twelve-month figure through Jun 2026 stood at 1.26 (down 27.45% YoY), and the FY2025 full-year result was 0.74, down 66.57% from the prior year.
• Price to Sales rose to 5.7 in Q2 2026 per TMCI's latest filing, from 1.84 in the prior quarter.
• Across five years, Price to Sales topped out at 55.29 in Q3 2022 and bottomed at 1.84 in Q1 2026.
• Historically, Price to Sales has averaged 19.86 across 5 years, with a median of 11.35 in 2025.
• The sharpest annual moves came in 2025 and 2026: Price to Sales climbed 6.28% in 2025, then tumbled 81.65% in 2026.
• Over 5 years, Price to Sales stood at 25.7 in 2022, then slumped by 50.75% to 12.66 in 2023, then tumbled by 46.42% to 6.78 in 2024, then plunged by 62.67% to 2.53 in 2025, then surged by 125.36% to 5.7 in 2026.
• According to Business Quant data, Price to Sales over the past three periods registered 5.7, 1.84, and 2.53 for Q2 2026, Q1 2026, and Q4 2025 respectively.